Letrozole

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Severe and Recurrent Endometriosis

Conditions

Severe and Recurrent Endometriosis

Trial Timeline

Oct 1, 2002 → Jun 1, 2006

NCT ID

NCT00240942

About Letrozole

Letrozole is a phase 2 stage product being developed by Novartis for Severe and Recurrent Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00240942. Target conditions include Severe and Recurrent Endometriosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01908556	Approved	UNKNOWN	Feb 1, 2009	—	is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
NCT00856050	Phase 2	Completed	Feb 1, 2009	Mar 1, 2014	Leiomyosarcoma
NCT00688909	Approved	Completed	Mar 1, 2008	Jun 1, 2009	Breast Cancer
NCT00549822	Phase 2	Terminated	Oct 1, 2007	Sep 1, 2013	Breast Cancer
NCT00414076	Phase 2	Terminated	Dec 19, 2006	Jul 13, 2017	Leiomyosarcoma
NCT00382070	Phase 3	Active	Aug 1, 2006	Apr 1, 2025	Breast Cancer
NCT00332852	Phase 3	Completed	Mar 1, 2006	—	Breast Cancer
NCT00330317	Phase 3	Completed	Feb 1, 2006	Nov 16, 2010	Breast Cancer
NCT00329940	Phase 3	Completed	Nov 1, 2005	—	Breast Cancer
NCT00171808	Phase 2	Completed	Apr 1, 2005	—	Endometrial Cancer
NCT00237133	Approved	Completed	Mar 1, 2003	Jan 21, 2009	Locally Advanced Breast Cancer
NCT00237224	Approved	Completed	Feb 1, 2003	—	Breast Cancer
NCT00291135	Phase 2	Completed	Jan 1, 2003	Oct 1, 2008	Breast Cancer
NCT00240942	Phase 2	Completed	Oct 1, 2002	Jun 1, 2006	Severe and Recurrent Endometriosis
NCT00333047	Phase 2/3	Completed	Jul 1, 2002	—	Metastatic Breast Cancer
NCT00241046	Approved	Terminated	Apr 1, 2002	—	Metastatic Breast Cancer
NCT00014638	Approved	Completed	Jan 1, 2001	Mar 1, 2002	Breast Cancer
NCT00535418	Phase 2/3	Completed	Jun 1, 2000	—	Breast Cancer
NCT00333086	Phase 2	Completed	Jan 1, 2000	—	Recurrent and Metastatic Endometrial Cancer

Competing Products

20 competing products in Severe and Recurrent Endometriosis

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	52
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
enzalutamide	Astellas Pharma	Phase 1	33
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	77
Alefacept	Astellas Pharma	Approved	85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
Cefiderocol	Shionogi	Approved	85
eritoran tetrasodium + Placebo	Eisai	Phase 3	77
Donepezil HCl	Eisai	Approved	85
Donepezil Hydrochloride (Aricept)	Eisai	Approved	85
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved